CADTH Canadian Drug Expert Committee recommendation: Risankizumab (Skyrizi -- Abbvie) : indication : adult patients with moderate to severe plaque psoriasis

The CADTH Canadian Drug Expert Committee (CDEC) recommends that risankizumab be reimbursed for the treatment of moderate to severe plaque psoriasis in adults only if the following conditions are met: In a manner similar to other biologics reimbursed for the treatment of moderate to severe plaque pso...

Full description

Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) CADTH May 2019, 2019
Edition:Version 1.0. (final)
Series:CADTH common drug review
Subjects:
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that risankizumab be reimbursed for the treatment of moderate to severe plaque psoriasis in adults only if the following conditions are met: In a manner similar to other biologics reimbursed for the treatment of moderate to severe plaque psoriasis. Treatment should be discontinued if a response to risankizumab has not been demonstrated by 16 weeks. The drug plan cost for risankizumab should not exceed the drug plan cost of treatment with the least costly biologic therapy reimbursed for the treatment of moderate to severe plaque psoriasis
Physical Description:1 PDF file (9 pages)